Sanctions for irregular marketing do “really hurt” drug companies, authority saysBMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c1970 (Published 12 April 2010) Cite this as: BMJ 2010;340:c1970
- Helen Mooney
The head of the panel that monitors the marketing of drugs in the United Kingdom has defended its system of regulation as being “very strong,” despite persistent offences by one company.
Procter & Gamble Pharmaceuticals UK was reprimanded in October 2009 for breaching the voluntary code of practice of the Association of the British Pharmaceutical Industry for using marketing material with the strapline “Confidence in colitis.” However, the Prescription Medicines Code of Practice Authority, the arm’s length body that enforces the code of practice on behalf of the association, had to take action against Procter & Gamble again this month over the same offence.
Heather Simmonds, the authority’s director and chairwoman of its code of practice panel, told the BMJ that sanctions levied …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial